Immune checkpoint inhibitors side effects and management

被引：58

作者：

Kourie, Hampig Raphael ^{[1
]}

Klastersky, Jean ^{[1
]}

机构：

[1] Univ Libre Bruxelles, Inst Jules Bordet, Ctr Tumeurs, Brussels, Belgium

来源：

IMMUNOTHERAPY | 2016年 / 8卷 / 07期

关键词：

checkpoint inhibitors; immunotherapy; side effects; AUTOIMMUNE HYPOPHYSITIS; METASTATIC MELANOMA; ADVERSE EVENTS; DOUBLE-BLIND; STAGE-III; IPILIMUMAB; NIVOLUMAB; THERAPY; PEMBROLIZUMAB; COMPLICATIONS;

D O I：

10.2217/imt-2016-0029

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The next decade in cancer therapy will be marked by the expansion of immunotherapies, namely immune checkpoint inhibitors. The increasing number and combination of checkpoint inhibitors and the variety of their mechanisms of action and indications will most likely multiply the side effects associated with these therapies and make their management more complicated and diversified. Given the growing rate of approval of different checkpoint inhibitors in different cancers in multiple settings, a review summarizing the major side effects of the new agents in use today and their management seems to be appropriate. Highlighting these adverse events and their management in a single review might help the daily practice of the physicians and consequently contribute the patient's safety and quality of life.

引用

页码：799 / 807

页数：9

共 38 条

[1] Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature [J].

Abdallah, Al-Ola ;

Herlopian, Aline ;

Ravilla, Rahul ;

Bansal, Meghana ;

Chandra-Reddy, Sowmya ;

Mahmoud, Fade ;

Ong, Shirley ;

Gokden, Murat ;

Hutchins, Laura .

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2016, 22 (03) :537-542

[2] Cytotoxic T-Lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer [J].

Blansfield, JA ;

Beck, KE ;

Tran, K ;

Yang, DC ;

Hughes, MS ;

Kammula, US ;

Royal, RE ;

Topalian, SL ;

Haworth, LR ;

Levy, C ;

Rosenberg, SA ;

Sherry, RM .

JOURNAL OF IMMUNOTHERAPY, 2005, 28 (06) :593-598

[3] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[4]

Callahan MK, 2011, J CLIN ONCOL S, V29, P2011

[5] Endocrine Side Effects Induced by Immune Checkpoint Inhibitors [J].

Corsello, Salvatore Maria ;

Barnabei, Agnese ;

Marchetti, Paolo ;

De Vecchis, Liana ;

Salvatori, Roberto ;

Torino, Francesco .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (04) :1361-1375

[6] Clinical Images: Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment [J].

de Velasco, Guillermo ;

Bermas, Boonie ;

Choueiri, Toni K. .

ARTHRITIS & RHEUMATOLOGY, 2016, 68 (02) :556-556

[7] The Emerging Toxicity Profiles of Anti-CTLA-4 Antibodies Across Clinical Indications [J].

Di Giacomo, Anna Maria ;

Biagioli, Maurizio ;

Maio, Michele .

SEMINARS IN ONCOLOGY, 2010, 37 (05) :499-507

[8] Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes [J].

Dillard, Troy ;

Yedinak, Chris G. ;

Alumkal, Joshi ;

Fleseriu, Maria .

PITUITARY, 2010, 13 (01) :29-38

[9] Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial [J].

Eggermont, Alexander M. M. ;

Chiarion-Sileni, Vanna ;

Grob, Jean-Jacques ;

Dummer, Reinhard ;

Wolchok, Jedd D. ;

Schmidt, Henrik ;

Hamid, Omid ;

Robert, Caroline ;

Ascierto, Paolo A. ;

Richards, Jon M. ;

Lebbe, Celeste ;

Ferraresi, Virginia ;

Smylie, Michael ;

Weber, Jeffrey S. ;

Maio, Michele ;

Konto, Cyril ;

Hoos, Axel ;

de Pril, Veerle ;

Gurunath, Ravichandra Karra ;

de Schaetzen, Gaetan ;

Suciu, Stefan ;

Testori, Alessandro .

LANCET ONCOLOGY, 2015, 16 (05) :522-530

[10]

Forde PM, 2012, ANTICANCER RES, V32, P4607

← 1 2 3 4 →